A series of anthraquinones with amino substituents at the 1,5 positions were found to induce interferon in mice. A prototype compound, 1,5-bis [(3-morpholi- Interferon, a broad-spectrum antiviral protein produced by virus-infected cells, appears to be an important component of the host's antiviral defense system. Several high-molecular-weight substances other than viruses can also cause cellular production of interferon and consequently protect animals against a variety of viral infections (6, 16). In addition, several relatively low-molecular-weight compounds also stimulate production of interferon in vivo (1, 4, 5, (9) (10) (11) (12) (13) . In an effort to broaden our understanding of molecular structural requirements necessary for in vivo or in vitro interferon stimulation, we initiated a search for molecules that possess the ability to induce interferon in mice and consequently protect them from lethal virus infection. During these studies several compounds were found to be active inducers. One of the most interesting of these agents was 1,5-bis[(3-morpholinopropyl)amino]-anthraquinone (Ia). This report summarizes our findings with Ia and three closely related structural analogs (Fig. 1) .
anthraquinone (Ib), which protected mice against virus infection at a dose as low as 8 mg/kg (less than 1/60 its maximum tolerated dose). Mice developed hyporeactivity to interferon induction if the same inducer was injected daily, although by alternating between different inducers the loss of interferon responsiveness could be avoided.
Interferon, a broad-spectrum antiviral protein produced by virus-infected cells, appears to be an important component of the host's antiviral defense system. Several high-molecular-weight substances other than viruses can also cause cellular production of interferon and consequently protect animals against a variety of viral infections (6, 16) . In addition, several relatively low-molecular-weight compounds also stimulate production of interferon in vivo (1, 4, 5, (9) (10) (11) (12) (13) . In an effort to broaden our understanding of molecular structural requirements necessary for in vivo or in vitro interferon stimulation, we initiated a search for molecules that possess the ability to induce interferon in mice and consequently protect them from lethal virus infection. During these studies several compounds were found to be active inducers. One of the most interesting of these agents was 1,5-bis[(3-morpholinopropyl)amino]-anthraquinone (Ia). This report summarizes our findings with Ia and three closely related structural analogs (Fig. 1 ).
Studies were initiated to determine the kinetics of the serum interferon response, what cells produce interferon in vivo, the minimum dose needed to protect mice against virus infection, and the maximum tolerated dose when compounds were given by any of several routes.
Particular attention was given to the development of a reduced ability of animals to respond to inducers when given in consecutive daily doses. It is well documented that animals and cells progressively lose their ability to respond to daily doses of the same interferon inducer (2, 3, 7, 8, 14, 15, 17) . Such a reduced response could limit the use of inducers as effective antiviral agents, and studies were therefore undertaken to determine if such a situation could be controlled or avoided. How quickly hyporeactivity developed in response to each inducer, how Interferon assay. Confluent monolayers of Lns cells grown in 35-ml plastic petri dishes were treated with 1 ml of an appropriate interferon dilution for 18 to 24 h at 37°C. The plaque reduction assay used vesicular stomatitis virus as the challenge virus and has been described (15) . An internal laboratory reference interferon standard was included with each interferon assay, and the sensitivity of each assay was compared with the International Murine Standard from the National Institutes of Health (6-002-904-511). In our system this standard had a mean titer of approximately 4,500 U/ml, compared with its accepted titer of 6,500 U/ml.
ALS. Horse anti-mouse lymphocyte serum (ALS) and normal horse serum were obtained from Microbiological Associates (Bethesda, Md.). Mice were injected intraperitoneally (i.p.) with 0.2 ml per day for 4 consecutive days.
X-irradiation. Mice received 650 R total body irradiation from a Philips MG-301 high-voltage X-ray machine as monitored using a model 550 Radocon III integrating rate electrometer system.
RESULTS
In an initial series of experiments the maximum tolerated dose, minimum protective dose, and minimum dose of compound required to induce detectable levels ofserum interferon were compared (Table 1) . Mice were injected i.p., subcutaneously, orally (p.o.), or intravenously with a single dose of compound, and the minimum dose required to induce interferon or protect mice from the lethal consequence of EMC virus infection was determined. Also the maximum dose of compound that could be given without causing mortality or more than a 10% decrease in body weight was determined. Of the anthraquinone compounds evaluated, Ia was tolerated at the highest concentrations but also required more compound to induce interferon or protect mice against the lethal consequences of virus infection. Ib and Id were equally tolerated by mice and were the most effective in inducing interferon and protecting mice against the lethal consequences of virus infection. In each case the miniimum dose of compound required to protect mice against infection was nearly equal to the minimum dose required to induce interferon, suggesting that interferon mediated the antiviral activity.
The antiviral substance present in mouse serum after treatment with each anthraquinone was characterized as an interferon. It was not sedimented by centrifugation at 100,000 x g for 2 h. The inhibitor was stable at pH 2 for at least Inteferon response. The ability of each of the anthraquinone compounds to induce circulating interferon levels in mice was evaluated. Mice received a single injection of one of the compounds near the maximum tolerated dose, and five mice per group were bled by cardiac puncture either 0, 2, 4, 6, 8, 12, 24, 36, or 48 h later. Serum was collected and assayed for interferon. Each of the molecules induced circulating interferon levels in mice (Fig. 2) . Compounds Ia and Ib were the most effective interferon inducers.
We next explored the ability of each of the molecules to induce circulatory interferon levels when given i.p., p.o., subcutaneously, or intravenously. The results presented in Figure 3 illustrate the serum interferon levels induced by compound Ia. The highest interferon levels were induced when the compound was given orally and reached peak titers 12 to 24 h after administration. Lower interferon levels were induced when the compound was given either subcutaneously or i.p. The lowest levels of interferon were indUced after intravenous injection. Similar results were obtained with each of the other anthraquinone compounds.
In an attempt to understand what cell populations were responding to each of the anthraquinone inducers, mice were treated with four consecutive daily doses of ALS or normal horse serum or were irradiated with 650 R of X-irradiation, and the serum interferon response to each of the inducers was evaluated 24 h after the last ALS treatment or 5 days after X-irradiation. X-irradiation suppressed the response to each of the anthraquinones (Ia, Ic, and Id = 500 mg/kg p.o.; lb = 100 mg/kg p.o.), whereas ALS had only a minor effect on each of them ( Table 3) . As controls, mice treated with ALS or X-irradiated were induced with poly(I:C) (100 ug i.p.), tilorone hydrochloride (250 mg/kg, p.o.), or NDV (107 plaque-forming units i.p.). X-irradiation suppressed the response to tilorone and NDV, whereas ALS affected the response to poly (I:C) and NDV.
To further explore the contribution of various cell populations to the interferon response of each of the anthraquinone inducers, mice were injected with compound Ia (500 mg/kg p.o.), and 0, 1, 2, 3, 4, 5, 6, 8, 12, or 24 h later five mice were sacrificed. Each was bled by cardiac puncture, and spleen, thymus, and lung tissues were collected. Organs were homogenized as 10% suspensions in minimal essential medium, and, after clarification by centrifugation, serum and supernatant fluids from tissue homogenates were assayed for interferon. High interferon levels were detected in spleen and thymus tissue collected from animals treated with compound Ia, and the levels of interferon induced in these organs cor- related with the levels of inteferon appearing in serum (Fig. 4) . Similar results were obtained with each of the anthraquinone inducers. Hyporeactivity. One of the problems associated with the use of interferon inducers as antiviral agents has been that, when the compounds are given in multiple dose regimens (daily doses), mice progressively lose their ability to respond to them. To evaluate whether this might be a restricting condition upon the use of the anthraquinone inducers, mice received oral doses of one of the inducers on 4 consecutive days. Twenty-four hours after administration of inducer, mice were bled. After the first dose of compound, animals lost their ability to respond to a second administration of the same interferon inducer (Fig. 5) .
To expand upon these observations, we next evaluated the length of time required for animals to regain their ability to respond to each of the interferon inducers. In these studies animals were injected on day 0 with a single dose of anthraquinone Ia, Ib, Ic, or Id. Then 1, 2, 3, 4, 5, 6, 7, or 8 days later animals received a second dose of the same compound. Recovery from hyporeactivity varied from inducer to inducer (Fig. 6 ). By day 3 to 5 after administration of the first dose of Ia, Ib, or Ic, animals had partially regained their ability to respond to inducer. From 6 to 7 days were required after the first dose of compound before mice fully regained their ability to respond to each of the inducers. Of the anthraquinones evaluated, Ic appeared to be the most severely affected. other hand, induced fairly high interferon levels through day 3 of infection. One approach to circumventing the development of hyporeactivity that results as a consequence of multiple daily doses of compound consists of alternating doses ofvarious interferon inducers. For example, on day 0 animals would receive an initial dose of a particular inducer, followed on day 2 by a dose of another unrelated inducer. To explore the feasibility of this approach, normal uninfected mice were initially injected with a single dose of an unrelated interferon inducer, ABMP (2-amino-5-bromo-6-methyl-4-pyrimidinol; 1,000 mg/kg p.o.), or anthraquinone Ia (500 mg/kg p.o.). Then daily after administration of the first dose of compound mice received a second, third, or fourth dose of the same or another interferon inducer (Table 5) . Five mice per group were bled by cardiac puncture after each dose of inducer when interferon levels were anticipated to be maximal. After the initial dose of ABMP, animals developed a hyporeactive response to a second dose of the same compound, but alteration of the inducer circumvented hyporeactivity (Table 5) . For example, mice that received an initial dose of ABMP followed by the same inducer on day 2 responded by producing only 500 U of interferon per ml of serum. If, however, the second compound was anthraquinone Ia or tilorone hydrochloride, the serum interferon response was high (3,000 to 4,000 U/ml). The same relationship held true on the third and fourth dose of inducer. feron inducers. Kinetics of interferon production induced by the four compounds were reasonably similar with respect to both time and titer of maximum interferon response. The only difference was that, when animals were injected intravenously, Ia induced fairly high interferon levels, whereas the other three compounds did not. Perhaps the most striking difference among the four compounds was with respect to the acute maximum tolerated doses. Ia was tolerated best, followed by Ic, Id, and Ib. The acute maximum tolerated dose for Ia was 4 to 32 times that of Tb, depending upon the route of drug administration. All four compounds were well tolerated when administered orally, and the highest titers of circulating interferon were also obtained after oral administration.
Animals rapidly developed a state of hyporeactivity when anthraquinones were given in daily dosage regimens. They also rapidly developed a state of hyporeactivity when compounds were administered to virus-infected animals. In this regard the molecules were quite similar to tilorone hydrochloride (15) . As we have previously reported with other inducers, animals required 4 to 6 days after an initial injection of a particular anthraquinone before they regained the full ability to respond to a second injection of the same compound (14) . Of Each of the anthraquinone molecules appeared to induce a nonlymphoid component of the reticuloendothelial system to either produce or participate in the interferon response. X-irradiation effectively wiped out the ability of animals to respond to each of the anthraquinone inducers, whereas ALS, which effectively inhibited the ability of mice to respond to NDV, had little if any effect on the ability of these animals to respond to any of the anthraquinone molecules. In vitro none of the anthraquinones was able to induce detectable levels of interferon when added to murine tissues or fibroblast cell cultures. However, after in vivo administration of the compound, high interferon levels were detected in spleen and thymus tissues which paralleled the interferon levels present in the serum. These results suggest that splenic and thymus tissue is involved in the induction process. The results with ALS and X-irradiation, however, suggest that it is not a lymphoid component that is responsible for the interferon response, but rather a nonlymphoid radiationsensitive cell such as the reticulocyte.
The potential of these compounds appears to be restricted by the same limitations that affect tilorone hydrochloride. They appeared to be slowly cleared from the circulation and reticuloendothelial systems of treated animals. Animals treated with a single dose of compound appeared to develop a severe hyporeactive state to further induction by the same compound. However, the results with alteration of daily doses between various interferon inducers suggest that the development of hyporeactivity could be circumvented by alternating inducers. Published reports on low-molecular-weight interferon inducers suggest that a wide diversity of structures can induce interferon in mice (1, 4, 5, 9-13), but only limited variations in the parent structures are permitted. This was found to be the case with the anthraquinone molecules. A wide range of structures were evaluated, with only the four listed in this report being significantly active. Perhaps when enough data on compounds and closely related inactive structures have been reported, some rationale for activity requirements can be formulated.
